Work

Phase II study of ceralasertib (ATR inhibitor) plus durvalumab in patients with advanced gastric cancer (AGC) who progressed on prior anti-PD-(L)1 therapy.

Year: 2026

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2026.44.16_suppl.4062

Authors: Sung Hee Lim, Minae An, Ji Eun Shin, Minsuk Kwon, Seung Tae Kim, Jeeyun Lee

Institutions: Samsung Medical Center, Sungkyunkwan University

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7162544138

Cites:

Cited by:

Related to: